Cumberland Pharmaceuticals Inc. ((CPIX)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
In a recent update, Cumberland Pharmaceuticals Inc. announced progress in their phase 2 clinical study titled A Phase 2 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Ifetroban in Patients With Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension (SSc-PAH). The study aims to evaluate the safety and effectiveness of ifetroban, a drug intended to treat these conditions, which are characterized by significant morbidity.
The study tests oral ifetroban, a drug designed to potentially reduce disease effects and prevent progression in patients with early-stage disease, while reversing established disease in those with longer disease duration. Participants receive either ifetroban or a placebo daily for a year.
This interventional study employs a randomized, parallel assignment model with quadruple masking, ensuring that participants, care providers, investigators, and outcomes assessors are unaware of the treatment allocations. The primary goal is treatment-focused.
Key dates include the study’s start in January 2017, with the latest update submitted in July 2025. These dates are crucial for tracking progress and anticipating results.
The study’s progress could influence Cumberland Pharmaceuticals’ stock performance and investor sentiment, especially if the results demonstrate significant efficacy. This could also impact the competitive landscape in the treatment of SSc and SSc-PAH.
The study remains active but is not recruiting, with further details available on the ClinicalTrials portal.